TABLE 2.

Summary of literature regarding patients on chemotherapeutic/immunosuppressive/imunomodulatory medications who developed COVID‐19

Rheumatology
Authors	Patient profile	Drugs	Outcome of COVID‐19
Monti et al 63	Chronic arthritis RA‐3, SpondyloArthritis (SpA)‐1	Methotrexate: 2 Leflunomide: 1 Etanercept: 2 Abatacept: 1 Low dose steroids: 2 (<5 mg/day prednisolone equivalent) Tofacitinib: 1	Hospital admission required: 1

Oncology
Authors	Patient profile (patients on active treatment for cancer at the time of COVID diagnosis)	Drugs	Outcome of COVID‐19
Liang et al 64	Four—Lung adenocarcinoma One—Chromophobe renal cell carcinoma One—Papillary thyroid microcarcinoma (age range: 47‐63 years)	Two on chemotherapy for advanced cancer Two on targeted therapy One on TSH inhibition therapy One—recurrence, on immunotherapy (further details not mentioned)	Severe disease in two of six (one on chemotherapeutic drugs and one on immunotherapy) (Ages: 58 and 63 years)
Yu et al 65	Five patients of non‐small cell lung cancer	Combinations of: Carboplatin, Pembrolizumab, Pemetrexed, Docetaxel, Cisplatin, Osimertinib, Sintilimab	Severe disease—one (on pemetrexed, cisplatin, and radiotherapy) (Age not mentioned)

Transplant recipients
Authors	Patient profile	Drugs	Outcome of COVID‐19
Gandolfini et al 66	Two renal transplant recipients (75 and 52 years of age)	Tacrolimus Mycophenolate mofetil Steroids	Survived—One Died—One
Huang et al 67	One renal transplant patient (58 years of age)	Mycophenolate mofetil Steroids	Died
	One Bone marrow transplant recipient (51 years of age)	Ciclosporine	Died